Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Page 1
Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators.
Curr Opin Pulm Med. 2023 Nov 1;29(6):580-586. doi: 10.1097/MCP.0000000000001006. Epub 2023 Aug 23.
Curr Opin Pulm Med. 2023.
PMID: 37611027
Review.
Retrospective studies have shown that patients taking HEMT with better baseline lung function have lower adherence to and prescription of inhaled medications. A randomized, controlled trial found that short-term discontinuation of dornase alfa or hypertonic saline was clin …
Retrospective studies have shown that patients taking HEMT with better baseline lung function have lower adherence to and prescription of in …
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.
Mayer-Hamblett N, Nichols DP, Odem-Davis K, Riekert KA, Sawicki GS, Donaldson SH, Ratjen F, Konstan MW, Simon N, Rosenbluth DB, Retsch-Bogart G, Clancy JP, VanDalfsen JM, Buckingham R, Gifford AH.
Mayer-Hamblett N, et al. Among authors: gifford ah.
Ann Am Thorac Soc. 2021 Aug;18(8):1397-1405. doi: 10.1513/AnnalsATS.202010-1336SD.
Ann Am Thorac Soc. 2021.
PMID: 33465316
Free PMC article.
The protocol is composed of two concurrent randomized controlled trials designed to evaluate the independent short-term effects of discontinuing hypertonic saline or dornase alfa, enabling individuals on both therapies to participate in one or both trials. ...
The protocol is composed of two concurrent randomized controlled trials designed to evaluate the independent short-term effects of di …
Item in Clipboard
Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study.
May TL, Gifford AH, Lahiri T, Black A, Trang J, Cornell AG, Gonzalez K, Morin S, Napier M, Duarte CW, Zuckerman JB.
May TL, et al. Among authors: gifford ah.
J Cyst Fibros. 2018 Jan;17(1):96-104. doi: 10.1016/j.jcf.2017.04.014. Epub 2017 Jun 2.
J Cyst Fibros. 2018.
PMID: 28579360
Free article.
Item in Clipboard
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R.
Mahler DA, et al. Among authors: gifford ah.
Respir Med. 2016 Jun;115:39-45. doi: 10.1016/j.rmed.2016.03.015. Epub 2016 Mar 22.
Respir Med. 2016.
PMID: 27215502
Free article.
Clinical Trial.
The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrrolate (GLY) 15.6 mug twice daily (b.i.d.), compared with an approved long-acting beta2-agonist (LABA), indacaterol (IND) 75 mug once daily (q …
The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrro …
Item in Clipboard
Cite
Cite